Reversing Resistance to Sunitinib: Findings May Help Patients W/ Deadly Kidney Cancer
Posted 02-19-2010 at 02:08 PM by admin
Reversing Resistance to Sunitinib: Findings May Help Patients With Deadly Kidney Cancer
ScienceDaily (Feb. 19, 2010) — Van Andel Research Institute (VARI) researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.
Kidney cancer is among the 10 most common cancers in both men and women, striking nearly 50,000 Americans in 2009 and killing more than 11,000. Renal cell carcinoma (RCC) accounts for 9 out of 10 kidney cancers, and ccRCC is the most common subtype, accounting for 8 out of 10 RCC cases.
"The research from Dr. Teh's (VARI) group is a critical step forward in understanding the mechanisms of response and resistance to the new standard of care therapies in renal cell carcinoma such as sunitinib," said Brian Rini, MD, Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute.
Sunitinib received FDA approval in 2006 and is a standard of care for both ccRCC and gastrointestinal stromal tumors. The drug is being investigated as a possible therapy for other cancers, including breast cancer, colorectal cancer, and non-small cell lung cancer.
Read the rest of the article here.
Copyright © 1995-2009 ScienceDaily LLC — All rights reserved
ScienceDaily (Feb. 19, 2010) — Van Andel Research Institute (VARI) researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.
Kidney cancer is among the 10 most common cancers in both men and women, striking nearly 50,000 Americans in 2009 and killing more than 11,000. Renal cell carcinoma (RCC) accounts for 9 out of 10 kidney cancers, and ccRCC is the most common subtype, accounting for 8 out of 10 RCC cases.
"The research from Dr. Teh's (VARI) group is a critical step forward in understanding the mechanisms of response and resistance to the new standard of care therapies in renal cell carcinoma such as sunitinib," said Brian Rini, MD, Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute.
Sunitinib received FDA approval in 2006 and is a standard of care for both ccRCC and gastrointestinal stromal tumors. The drug is being investigated as a possible therapy for other cancers, including breast cancer, colorectal cancer, and non-small cell lung cancer.
Read the rest of the article here.
Copyright © 1995-2009 ScienceDaily LLC — All rights reserved
Total Comments 0
Comments
Recent Blog Entries by admin
- Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand (07-29-2010)
- Potential Biomarkers of VELCADE Activity in Patients w/Relapsed Mantle Cell Lymphoma (07-29-2010)
- UT Health Science Center team finds adrenal cancer gene (07-29-2010)
- £50m boost to help cancer patients (07-29-2010)
- Generic Gemzar may appear soon (07-29-2010)
